Fractalkine levels in patients with vascular dementia, Alzheimer’s disease and mild cognitive impairment

•Increased fractalkine levels have been reported in patients with AD, and MCI.•Soluble fractalkine increased in AD, VAD, and MCI than in controls. The VAD had the highest levels.•Patients with mild and moderate AD had higher levels of fractalkine than severe AD.•Higher fractalkine levels in early AD...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical neuroscience 2022-02, Vol.96, p.229-230
Main Authors: Teksut, Tuba Kuz, Irkec, Ceyla, Altiparmak, Taylan, Fidan, Isil
Format: Article
Language:English
Subjects:
Alzheimer Disease
Alzheimer’s disease
Chemokine CX3CL1
Cognitive Dysfunction
CX3CL1
Dementia, Vascular
Fractalkine
Humans
Mild cognitive impairment
Vascular dementia
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Increased fractalkine levels have been reported in patients with AD, and MCI.•Soluble fractalkine increased in AD, VAD, and MCI than in controls. The VAD had the highest levels.•Patients with mild and moderate AD had higher levels of fractalkine than severe AD.•Higher fractalkine levels in early AD, supports the early involvement of inflammation in AD even in MCI.
ISSN:0967-5868
1532-2653
DOI:10.1016/j.jocn.2021.12.014